These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29929462)

  • 1. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.
    Haaf M; Leicht G; Curic S; Mulert C
    Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.
    Thiebes S; Leicht G; Curic S; Steinmann S; Polomac N; Andreou C; Eichler I; Eichler L; Zöllner C; Gallinat J; Hanganu-Opatz I; Mulert C
    J Psychiatry Neurosci; 2017 Jun; 42(4):273-283. PubMed ID: 28556775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI.
    Northoff G; Richter A; Bermpohl F; Grimm S; Martin E; Marcar VL; Wahl C; Hell D; Boeker H
    Schizophr Res; 2005 Jan; 72(2-3):235-48. PubMed ID: 15560968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.
    Musso F; Brinkmeyer J; Ecker D; London MK; Thieme G; Warbrick T; Wittsack HJ; Saleh A; Greb W; de Boer P; Winterer G
    Neuroimage; 2011 Sep; 58(2):508-25. PubMed ID: 21723949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia.
    Grent-'t-Jong T; Rivolta D; Gross J; Gajwani R; Lawrie SM; Schwannauer M; Heidegger T; Wibral M; Singer W; Sauer A; Scheller B; Uhlhaas PJ
    Brain; 2018 Aug; 141(8):2511-2526. PubMed ID: 30020423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI.
    Gaebler AJ; Fakour N; Stöhr F; Zweerings J; Taebi A; Suslova M; Dukart J; Hipp JF; Adhikari BM; Kochunov P; Muthukumaraswamy SD; Forsyth A; Eggermann T; Kraft F; Kurth I; Paulzen M; Gründer G; Schneider F; Mathiak K
    Transl Psychiatry; 2023 Feb; 13(1):59. PubMed ID: 36797233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.
    Khlestova E; Johnson JW; Krystal JH; Lisman J
    J Neurosci; 2016 Nov; 36(44):11151-11157. PubMed ID: 27807157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
    Ehrlichman RS; Gandal MJ; Maxwell CR; Lazarewicz MT; Finkel LH; Contreras D; Turetsky BI; Siegel SJ
    Neuroscience; 2009 Jan; 158(2):705-12. PubMed ID: 19015010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reviewing the ketamine model for schizophrenia.
    Frohlich J; Van Horn JD
    J Psychopharmacol; 2014 Apr; 28(4):287-302. PubMed ID: 24257811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
    Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
    Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice.
    Jeevakumar V; Driskill C; Paine A; Sobhanian M; Vakil H; Morris B; Ramos J; Kroener S
    Behav Brain Res; 2015 Apr; 282():165-75. PubMed ID: 25591475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine Alters Functional Gamma and Theta Resting-State Connectivity in Healthy Humans: Implications for Schizophrenia Treatment Targeting the Glutamate System.
    Curic S; Andreou C; Nolte G; Steinmann S; Thiebes S; Polomac N; Haaf M; Rauh J; Leicht G; Mulert C
    Front Psychiatry; 2021; 12():671007. PubMed ID: 34177660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.
    Rowland LM; Bustillo JR; Mullins PG; Jung RE; Lenroot R; Landgraf E; Barrow R; Yeo R; Lauriello J; Brooks WM
    Am J Psychiatry; 2005 Feb; 162(2):394-6. PubMed ID: 15677610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance imaging study.
    Fu CH; Abel KM; Allin MP; Gasston D; Costafreda SG; Suckling J; Williams SC; McGuire PK
    Psychopharmacology (Berl); 2005 Nov; 183(1):92-102. PubMed ID: 16228196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
    Schmidt A; Bachmann R; Kometer M; Csomor PA; Stephan KE; Seifritz E; Vollenweider FX
    Neuropsychopharmacology; 2012 Mar; 37(4):865-75. PubMed ID: 22030715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia.
    Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA
    Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the central effects of chronic ketamine administration in an adolescent primate model by functional magnetic resonance imaging (fMRI).
    Yu H; Li Q; Wang D; Shi L; Lu G; Sun L; Wang L; Zhu W; Mak YT; Wong N; Wang Y; Pan F; Yew DT
    Neurotoxicology; 2012 Jan; 33(1):70-7. PubMed ID: 22178134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.